FOCUS online – “Biontech vaccine for the general public initially had significant deficiencies”

BioNTech submitted two manufacturing processes to the EMA: "Process 1" using PCR for a vaccine and "Process 2" using E. coli bacteria for the general population. Dr. Marco Rogert highlights significant differences and impurities in the vaccine produced using "Process 2," which has been administered to millions of people.

To the article on FOCUS online »